PHD1/2

Class

Prolyl hydroxylase inhibitor

PHD1 and PHD2 are prolyl hydroxylase enzymes that act as cellular oxygen sensors. Under normal oxygen levels, they chemically modify (hydroxylate) hypoxia-inducible factor (HIF) proteins, marking them for rapid degradation. When oxygen is scarce, this modification slows, HIF accumulates, and it switches on a broad transcriptional program that includes erythropoietin—the hormone driving red blood cell production—along with genes that improve iron absorption and utilization. Inhibiting PHD1/2 pharmacologically mimics this low-oxygen signal even when tissue oxygen is normal, stimulating the body's own erythropoietin production and iron-handling machinery. This mechanism is relevant wherever red blood cell production is impaired despite adequate erythropoietin-producing capacity, such as anemia associated with chronic kidney disease or chronic inflammatory conditions, where inflammation or iron restriction blunts the normal response. Because the hypoxia-inducible factor pathway also controls blood vessel growth and metabolic adaptation, one design strategy—restricting a drug's absorption to the gut—aims to confine hydroxylase inhibition mainly to intestinal tissue. This localizes the desired effects on iron uptake and absorption while limiting activation of the same pathway throughout the rest of the body, reducing exposure of tissues where broader hypoxia-inducible factor signaling is not needed for the therapeutic goal.